IL6 and Parkinson disease: Blocking IL-6 signaling in a purely PD context (PD neurons/PD astrocyte) with a specific antibody FDA-approved (Tocilizumab) prevented neuronal degeneration significantly more compared with control neurons treated with PD-ACM.